Faculty

Institution

Unit

Venue

Carl Maki

Professor

Rush University

Affiliations

College of Health Sciences

Department Of Clinical Nutrition

Rush Medical College

Department Of Anatomy And Cell Biology

Rush University

Carl Maki is currently serving as a College Of Health Sciences Professor at Rush University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Carl Maki

Rush University

Professor

You can click a keyword to filter the displayed items

cell biology oncogenes tumor biology cancer cells cancer biology tumor suppressors molecular biology cell signaling molecular cancer molecular cell biology cell regulation cancer research cell death pharmacology therapeutic targets molecular and cellular biology breast cancer carcinogenesis cancer genetics breast oncology biochemistry medicinal research signal transduction autophagy apoptosis signaling pathways enzyme inhibition anti-cancer agents cell autophagy cell research cellular biochemistry protein science cellular therapy cell metabolism nuclear organization cancer treatment tumor targeting genome instability cellular senescence cancer growth nucleic acids cancer imaging cellular physiology molecular regulation cell cycle protein function endocrine-related cancers drug targets cell therapy cell proliferation therapy-resistant tetraploid cells mdm2 binding conformational change heat-shock protein 90 supramolecular chemistry novel therapies molecular pathways cell fate determination hormonal receptor radiation biology colorectal cancer transcription regulation gene regulation decision analysis small-molecule mdm2 antagonists p53 mutations p53 nuclear export sequential changes functional interactions p21 stability prosurvival autophagy critical roles nitric oxide nutlin-3a removal is persistent p21 expression senescence-like arrest metastasis translational research gynecologic oncology oral pathology neuro-oncology dna repair anatomical pathology gynecology ovarian cancer pathology translational medicine medicine cancer care molecular diagnostics stem cells cervical cancer tumor microenvironment jama oncology cellular differentiation dermatology surgical oncology urology gynecologic cancers sarcoma surgical pathology lung cancer cancer letter biomedical informatics thoracic oncology radiation oncology systems biology brain tumor research cancer discovery mesothelioma histopathology oncology experimental medicine molecular medicine

Notable Scholarly Works

Notable Federal Grants

Collaborators

Dormancy Exit Correlates With Creb1 Reactivation That is a Potential Target to Overcome Endocrine Therapy Resistance in Er+ Breast Cancer Cells. iScience (2026)

breast oncologymolecular and cellular biologyoncogenesendocrine therapy resistancedormancy exit correlatestumor biologycancer biologycreb1 reactivationcell signalingcellular senescencecell biologydevelopmental biologymolecular cell biologytumor suppressorscancer cellscell regulationbreast cancer

Supplemental Tables- a Four-Gene Signature Predicts Response to Ttk Inhibition and Taxane Therapy in Breast Cancer. Figshare (2026)

breast oncologyoncogenespathologytumor biologycancer biologycell biologyfour-gene signaturemolecular cancerttk inhibitionmolecular diagnosticstaxane therapycancer geneticscancer genomicsbreast cancer

Creb1 Promotes Dormancy Exit and is a Target to Overcome Endocrine Therapy Resistance in Er+ Breast Cancer Cells. SSRN Electronic Journal (2025)

molecular and cellular biologyoncogenestumor biologycancer biologycell signalingcellular senescencecell biologymolecular cancersignaling pathwaysdevelopmental biologymolecular cell biologytumor suppressorscancer cellsgene expressioncell regulationbreast cancer

Figure S7 From Coinhibition of Aurora Kinase B and Suv4-20H Induces Synthetic Lethality in Wild-Type P53-Deficient Cancer Cells. (2025)

oncogenestumor biologycell biologyaurora kinase bcancer researchtumor suppressorsoncogenic agentfigure s7systems biologycancer cellscell regulationcancer biology

Isg20L2 as a Driver in the Proliferation and Invasion of Lung Adenocarcinoma via Nkx2-1 Regulation. Translational Cancer Research (2025)

lung adenocarcinomaoncogenespathologytumor biologycell biologymolecular cancerlung cancercarcinogenesisnkx2-1 regulationcancer researchtumor suppressorsoncogenic agentcancer growththoracic oncologycancer cellscancer biology

Determinants of Aurora Kinase B Inhibitor Sensitivity in Small Cell Lung Cancer. Translational Lung Cancer Research (2024)

oncogenesradiation oncologybronchial neoplasmcell biologylung canceroncogenic agenttherapeutic targetsthoracic oncologycancer cells

Novel Markers of Mcl1 Inhibitor Sensitivity in Triple-Negative Breast Cancer Cells. Journal of Biological Chemistry (2024)

breast oncologyoncogenesnovel markerscancer biologyimmunologycell biologymolecular cancertherapeutic targetscancer cellsmcl1 inhibitor sensitivitybreast cancer

Potential Biomarkers for Mcl1 Inhibitor Sensitivity. Cell Signaling (2024)

oncogenesdrug targetsmedicinal researchbiomarker targetmolecular cancercancer discoverypharmacologytherapeutic targetsdrug discoverypharmacological researchpotential biomarkers

Cse1L is a Negative Regulator of the Rb-Dream Pathway in P53 Wild-Type Nsclc and Can Be Targeted Using an Hdac1/2 Inhibitor. Scientific Reports (2023)

oncogeneshdac1/2 inhibitorcell signalingcell biologymolecular cancermolecular cell biologytumor suppressorsoncogenic agentmolecular biologytherapeutic targetsrb-dream pathwaycancer cellscell regulationp53 wild-type nsclccancer biology

Supplementary Data From Nutlin-3A Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of P53 Wild-Type Cancer Cells. (2023)

molecular and cellular biologyoncogenestumor biologysupplementary datacell migrationcell deathcell signalinginvasion capacitycell biologymolecular cancercancer researchmolecular cell biologytumor suppressorsmolecular biologycancer growthcancer cellscell regulationcancer biology

1
2
3
4
5
6
10 / page

Carl Maki

Professor

Rush University

Affiliations

College of Health Sciences

Department Of Clinical Nutrition

Rush Medical College

Department Of Anatomy And Cell Biology

Rush University

Carl Maki is currently serving as a College Of Health Sciences Professor at Rush University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Carl Maki

Rush University

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Dormancy Exit Correlates With Creb1 Reactivation That is a Potential Target to Overcome Endocrine Therapy Resistance in Er+ Breast Cancer Cells. iScience (2026)

Supplemental Tables- a Four-Gene Signature Predicts Response to Ttk Inhibition and Taxane Therapy in Breast Cancer. Figshare (2026)

breast oncologyoncogenespathologytumor biologycancer biologycell biologyfour-gene signaturemolecular cancerttk inhibitionmolecular diagnosticstaxane therapycancer geneticscancer genomicsbreast cancer

Creb1 Promotes Dormancy Exit and is a Target to Overcome Endocrine Therapy Resistance in Er+ Breast Cancer Cells. SSRN Electronic Journal (2025)

Figure S7 From Coinhibition of Aurora Kinase B and Suv4-20H Induces Synthetic Lethality in Wild-Type P53-Deficient Cancer Cells. (2025)

oncogenestumor biologycell biologyaurora kinase bcancer researchtumor suppressorsoncogenic agentfigure s7systems biologycancer cellscell regulationcancer biology

Isg20L2 as a Driver in the Proliferation and Invasion of Lung Adenocarcinoma via Nkx2-1 Regulation. Translational Cancer Research (2025)

Determinants of Aurora Kinase B Inhibitor Sensitivity in Small Cell Lung Cancer. Translational Lung Cancer Research (2024)

oncogenesradiation oncologybronchial neoplasmcell biologylung canceroncogenic agenttherapeutic targetsthoracic oncologycancer cells

Novel Markers of Mcl1 Inhibitor Sensitivity in Triple-Negative Breast Cancer Cells. Journal of Biological Chemistry (2024)

breast oncologyoncogenesnovel markerscancer biologyimmunologycell biologymolecular cancertherapeutic targetscancer cellsmcl1 inhibitor sensitivitybreast cancer

Potential Biomarkers for Mcl1 Inhibitor Sensitivity. Cell Signaling (2024)

oncogenesdrug targetsmedicinal researchbiomarker targetmolecular cancercancer discoverypharmacologytherapeutic targetsdrug discoverypharmacological researchpotential biomarkers

Cse1L is a Negative Regulator of the Rb-Dream Pathway in P53 Wild-Type Nsclc and Can Be Targeted Using an Hdac1/2 Inhibitor. Scientific Reports (2023)

Supplementary Data From Nutlin-3A Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of P53 Wild-Type Cancer Cells. (2023)

1
2
3
4
5
6
10 / page